Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise stress in patients with coronary artery disease and exercise inducible ischaemia

Trial Profile

Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise stress in patients with coronary artery disease and exercise inducible ischaemia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Coronary artery disease; Myocardial ischaemia
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors IRIS
  • Most Recent Events

    • 30 Sep 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 07 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-000783-98).
    • 19 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top